These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37793012)

  • 1. Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation.
    Cao Y; Zheng X; Zhang H; Wang M; Guo W; Chen X; Zhai W; Wei J; Yang D; Huang Y; Pang A; Feng S; Jiang E; Han M
    Hematol Oncol; 2024 Jan; 42(1):e3232. PubMed ID: 37793012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Wattebled KJ; Drumez E; Coiteux V; Magro L; Srour M; Chauvet P; Quesnel B; Duhamel A; Yakoub-Agha I; Beauvais D
    Ann Hematol; 2022 Jun; 101(6):1321-1331. PubMed ID: 35352216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia.
    Feng Y; Chen T; Zhang Y; Yao H; Wang P; Wang L; Cassady K; Zou Z; Liu Y; Zhao L; Gao L; Zhang X; Kong P
    Front Immunol; 2023; 14():1182251. PubMed ID: 37435080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
    Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
    Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
    Fei X; Zhang S; Gu J; Wang J
    Cancer Med; 2023 Mar; 12(6):6877-6888. PubMed ID: 36411731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
    Keruakous AR; Holter-Chakrabarty J; Schmidt SA; Khawandanah MO; Selby G; Yuen C
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):52-60. PubMed ID: 36634281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
    Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
    Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
    Lou D; Liu L; Yan XQ; Gu FN; Zhang YP; Qin WW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
    Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
    Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
    Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
    Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
    Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.
    Araie H; Arai Y; Kida M; Aoki J; Uchida N; Doki N; Fukuda T; Tanaka M; Ozawa Y; Sawa M; Katayama Y; Matsuo Y; Onizuka M; Kanda Y; Kawakita T; Kanda J; Atsuta Y; Yanada M;
    Ann Hematol; 2023 Oct; 102(10):2879-2893. PubMed ID: 37477669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.